To this aim, we retrospectively analyzed the ERCC1, ERCC2, and ERCC5 expression levels and the genotypic characterization of a panel of five single nucleotide polymorphisms (SNPs) of these genes in a cohort of patients with ED-SCLC who received platinum/etoposide regimens. This evidence concerns the gene ERCC2 and small cell lung carcinoma.